Drug Profile
Research programme: inflammation and pain therapeutics - Kalypsys
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Kalypsys
- Class Small molecules
- Mechanism of Action Nitric oxide synthase type II inhibitors; P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Inflammation; Neuropathic pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in USA (PO)